The in vitro activity of N-fonnimidoyl thienamycin (MK0787), a stable congener of thienamycin, was determined against 200 species of aerobic and 84 species of anaerobic bacteria. The compound was highly active against resistant gramnegative bacilli, penicillin-resistant Staphylococcus aureus, enterococci, and anaerobic bacteria. The new derivative of thienamycin was more active than the parent compound, probably reflecting the stability of the analog. N-Formimidoyl thienamycin (MK0787) is a stable crystalline derivative of thienamycin (4). Previous studies from this laboratory have demonstrated that thienamycin has broad antimicrobial activity against both aerobic and anaerobic bacteria (5). For example, thienamycin was highly active against gram-negative bacilli and penicillin-resistant Staphylococcus aureus. In addition, the activity of this novel fi-lactam antibiotic against anaerobic bacteria was comparable to that of metronidazole. However, the parent compound, lacking stability at high concentrations, was considered unsuitable as a therapeutic agent for serious infections. MK0787 is a congener of thienamycin that appears to possess the stability and antimicrobial spectrum of a clinically useful drug. This report documents the excellent in vitro activity of MK0787 against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria.
N-Formimidoyl thienamycin (MK0787) is a stable crystalline derivative of thienamycin (4) . Previous studies from this laboratory have demonstrated that thienamycin has broad antimicrobial activity against both aerobic and anaerobic bacteria (5) . For example, thienamycin was highly active against gram-negative bacilli and penicillin-resistant Staphylococcus aureus. In addition, the activity of this novel fi-lactam antibiotic against anaerobic bacteria was comparable to that of metronidazole. However, the parent compound, lacking stability at high concentrations, was considered unsuitable as a therapeutic agent for serious infections. MK0787 is a congener of thienamycin that appears to possess the stability and antimicrobial spectrum of a clinically useful drug. This report documents the excellent in vitro activity of MK0787 against a broad range of gram-positive and gram-negative aerobic and anaerobic bacteria.
Standard Pseudomonas aeruginosa ATCC 27853, B. fragilis TAL 10, and Peptococcus magnus TAL 169. The control anaerobic strains were originally obtained from Vera Sutter (Los Angeles, Calif.) and have been used routinely as control strains in our laboratory. Antibiotic susceptibility of aerobes and facultative organisms was determined by the microtiter technique; the susceptibility of anaerobes was determined by a modification of the agar dilution method. Both procedures have been described previously (1, 5) .
MK0787 possessed excellent activity against all ofthe gram-negative facultative bacilli tested, including E. coli and P. aeruginosa (Table 1 ).
All tested bacteria in this group were inhibited by 4 ,ug or less/ml, except one strain of Serratia that required 8 fg/ml for inhibition. MK0787 was more active than gentamicin, amikacin, or carbenicillin. against gram-negative bacilli and was even active against organisms resistant to these three compounds.
This new analog of thienamycin possessed good activity against most facultative gram-positive cocci (Table 1) . It had activity similar to that of nafcillin against S. aureus. MK0787 also displayed good activity against enterococci. The only notable exception was Staphylococcus epidermidis, 3 of 20 strains of which were resistant, requiring 32,ug/ml for inhibition.
MK0787 showed excellent activity against the anaerobic bacteria tested ( none of the tested strains of B. fragilis required more than 1.0 ,ug of MK0787 per ml for inhibition. This drug also inhibited B. fragilis strains that were highly resistant to other antibiotics, including strains known to produce high levels of ,B-lactamase, those with high 'resistance to clindamycin, and the only strain resistant to metronidazole so far isolated. The uniform activity of MK0787 against B. fragilis at low concentrations indicates that it effectively penetrates to the active site and is most likely resistant to the /-lactamases (6) .
MK0787 also displayed good activity against anaerobic gram-positive cocci and clostridia.
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